APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharma and Health Care

The pharmaceutical industry, it is composed of companies developing and manufacturing innovative medicines and generic pharmaceuticals, as well as over–the-counter drug products. The sector is made up of a number of sub-sectors that service different market segments.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The pharmaceutical industry, it is composed of companies developing and manufacturing innovative medicines and generic pharmaceuticals, as well as over–the-counter drug products. The sector is made up of a number of sub-sectors that service different market segments.

Health products are vitamins, minerals, herbal medicines, homeopathic preparations, probiotics and even some traditional medicines are also prescribed by doctor or any equivalent physician.

In this report, we mainly study the pharma and healthcare product.

Selected research

Market Outlook & Growth Opportunities

Global Pharma and Health Care Market Outlook and Growth Opportunities 2026

30 December 2025201 pages

Choose your research edition.

Industry ResearchPharma and Health Care Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharma and Health Care Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Pharma and Health Care Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharma and Health Care Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharma and Health Care Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The pharmaceutical industry, it is composed of companies developing and manufacturing innovative medicines and generic pharmaceuticals, as well as over–the-counter drug products. The sector is made up of a number of sub-sectors that service different market segments.

Health products are vitamins, minerals, herbal medicines, homeopathic preparations, probiotics and even some traditional medicines are also prescribed by doctor or any equivalent physician.

In this report, we mainly study the pharma and healthcare product.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 50%. Following North America, Asia-Pacific is the second largest consumption place with the consumption market share of 25%.

Market competition is intense. The key players are Johnson & Johnson, Novartis, Roche, AbbVie, Merck & Co., etc. The top five vendors held 20% of the market share.

This report provides an overview of the global Pharma and Health Care market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharma and Health Care and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharma and Health Care revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharma and Health Care market.

Pharma and Health Care Segment by Company

Johnson & Johnson

Novartis

Roche

AbbVie

Merck & Co.

Bristol Myers Squibb

GlaxoSmithKline

Pfizer

Sanofi

Takeda

AstraZeneca

Bayer

Eli Lilly & Co.

Gilead Sciences

Amgen

Novo Nordisk

Teva

Boehringer Ingelheim

Biogen

Astellas

Pharma and Health Care Segment by Format

Bottle

Blister

Others

Pharma and Health Care Segment by Prescription

OTC Drugs

Prescription Drugs

Pharma and Health Care Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharma and Health Care status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharma and Health Care key companies, revenue, market share, and recent developments.

3. To split the Pharma and Health Care breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharma and Health Care market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharma and Health Care significant trends, drivers, influence factors in global and regions.

6. To analyze Pharma and Health Care competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma and Health Care market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharma and Health Care and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma and Health Care.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharma and Health Care industry.

Chapter 3: Detailed analysis of Pharma and Health Care company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharma and Health Care in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharma and Health Care in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharma and Health Care Industry Trends Table 2. Pharma and Health Care Industry Drivers Table 3. Pharma and Health Care Industry Opportunities and Challenges Table 4. Pharma and Health Care Industry Restraints Table 5. Global Pharma and Health Care Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharma and Health Care Revenue Share by Company (2021-2026) Table 7. Global Pharma and Health Care Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharma and Health Care Key Company Manufacturing Base & Headquarters Table 9. Global Pharma and Health Care Company, Product Type & Application Table 10. Global Pharma and Health Care Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharma and Health Care by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bottle Table 15. Significant Companies of Blister Table 16. Significant Companies of Others Table 17. Global Pharma and Health Care Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Pharma and Health Care Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Pharma and Health Care Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Pharma and Health Care Sales Value Share by Type (2021-2026) Table 21. Global Pharma and Health Care Sales Value Share by Type (2027-2032) Table 22. Significant Companies of OTC Drugs Table 23. Significant Companies of Prescription Drugs Table 24. Global Pharma and Health Care Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pharma and Health Care Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Pharma and Health Care Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Pharma and Health Care Sales Value Share by Application (2021-2026) Table 28. Global Pharma and Health Care Sales Value Share by Application (2027-2032) Table 29. Global Pharma and Health Care Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pharma and Health Care Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Pharma and Health Care Sales Value Share by Region (2021-2026) Table 32. Global Pharma and Health Care Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Pharma and Health Care Sales Value Share by Region (2027-2032) Table 34. Global Pharma and Health Care Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Pharma and Health Care Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Pharma and Health Care Sales Value Market Share by Country (2021-2026) Table 37. Global Pharma and Health Care Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Pharma and Health Care Sales Value Market Share by Country (2027-2032) Table 39. Johnson & Johnson Company Information Table 40. Johnson & Johnson Business Overview Table 41. Johnson & Johnson Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Johnson & Johnson Pharma and Health Care Product Portfolio Table 43. Johnson & Johnson Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis Pharma and Health Care Product Portfolio Table 48. Novartis Recent Development Table 49. Roche Company Information Table 50. Roche Business Overview Table 51. Roche Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Roche Pharma and Health Care Product Portfolio Table 53. Roche Recent Development Table 54. AbbVie Company Information Table 55. AbbVie Business Overview Table 56. AbbVie Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. AbbVie Pharma and Health Care Product Portfolio Table 58. AbbVie Recent Development Table 59. Merck & Co. Company Information Table 60. Merck & Co. Business Overview Table 61. Merck & Co. Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Merck & Co. Pharma and Health Care Product Portfolio Table 63. Merck & Co. Recent Development Table 64. Bristol Myers Squibb Company Information Table 65. Bristol Myers Squibb Business Overview Table 66. Bristol Myers Squibb Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bristol Myers Squibb Pharma and Health Care Product Portfolio Table 68. Bristol Myers Squibb Recent Development Table 69. GlaxoSmithKline Company Information Table 70. GlaxoSmithKline Business Overview Table 71. GlaxoSmithKline Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GlaxoSmithKline Pharma and Health Care Product Portfolio Table 73. GlaxoSmithKline Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Pharma and Health Care Product Portfolio Table 78. Pfizer Recent Development Table 79. Sanofi Company Information Table 80. Sanofi Business Overview Table 81. Sanofi Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sanofi Pharma and Health Care Product Portfolio Table 83. Sanofi Recent Development Table 84. Takeda Company Information Table 85. Takeda Business Overview Table 86. Takeda Pharma and Health Care Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Takeda Pharma and Health Care Product Portfolio Table 88. Takeda Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. AstraZeneca Pharma and Health Care Product Portfolio Table 93. AstraZeneca Recent Development Table 94. Bayer Company Information Table 95. Bayer Business Overview Table 96. Bayer Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bayer Pharma and Health Care Product Portfolio Table 98. Bayer Recent Development Table 99. Eli Lilly & Co. Company Information Table 100. Eli Lilly & Co. Business Overview Table 101. Eli Lilly & Co. Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Eli Lilly & Co. Pharma and Health Care Product Portfolio Table 103. Eli Lilly & Co. Recent Development Table 104. Gilead Sciences Company Information Table 105. Gilead Sciences Business Overview Table 106. Gilead Sciences Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Gilead Sciences Pharma and Health Care Product Portfolio Table 108. Gilead Sciences Recent Development Table 109. Amgen Company Information Table 110. Amgen Business Overview Table 111. Amgen Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Amgen Pharma and Health Care Product Portfolio Table 113. Amgen Recent Development Table 114. Novo Nordisk Company Information Table 115. Novo Nordisk Business Overview Table 116. Novo Nordisk Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novo Nordisk Pharma and Health Care Product Portfolio Table 118. Novo Nordisk Recent Development Table 119. Teva Company Information Table 120. Teva Business Overview Table 121. Teva Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Teva Pharma and Health Care Product Portfolio Table 123. Teva Recent Development Table 124. Boehringer Ingelheim Company Information Table 125. Boehringer Ingelheim Business Overview Table 126. Boehringer Ingelheim Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Boehringer Ingelheim Pharma and Health Care Product Portfolio Table 128. Boehringer Ingelheim Recent Development Table 129. Biogen Company Information Table 130. Biogen Business Overview Table 131. Biogen Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Biogen Pharma and Health Care Product Portfolio Table 133. Biogen Recent Development Table 134. Astellas Company Information Table 135. Astellas Business Overview Table 136. Astellas Pharma and Health Care Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Astellas Pharma and Health Care Product Portfolio Table 138. Astellas Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Pharma and Health Care Product Image Figure 2. Global Pharma and Health Care Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharma and Health Care Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharma and Health Care Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bottle Image Figure 8. Blister Image Figure 9. Others Image Figure 10. Global Pharma and Health Care Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Pharma and Health Care Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Pharma and Health Care Sales Value Share by Type (2021-2032) Figure 13. OTC Drugs Image Figure 14. Prescription Drugs Image Figure 15. Global Pharma and Health Care Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pharma and Health Care Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pharma and Health Care Sales Value Share by Application (2021-2032) Figure 18. Global Pharma and Health Care Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Pharma and Health Care Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Pharma and Health Care Sales Value (2021-2032) & (US$ Million) Figure 21. North America Pharma and Health Care Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Pharma and Health Care Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Pharma and Health Care Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Pharma and Health Care Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Pharma and Health Care Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Pharma and Health Care Sales Value (2021-2032) & (US$ Million) Figure 27. South America Pharma and Health Care Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Pharma and Health Care Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Pharma and Health Care Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Pharma and Health Care Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Pharma and Health Care Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Pharma and Health Care Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Bottle
  • Blister
  • Others
Applications
  • OTC Drugs
  • Prescription Drugs
Companies covered
  • Johnson & Johnson
  • Novartis
  • Roche
  • AbbVie
  • Merck & Co.
  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Takeda
  • AstraZeneca
  • Bayer
  • Eli Lilly & Co.
  • Gilead Sciences
  • Amgen
  • Novo Nordisk
  • Teva
  • Boehringer Ingelheim
  • Biogen
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharma and Health Care Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharma and Health Care Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharma and Health Care Market Dynamics
  1. 2.1 Pharma and Health Care Industry Trends
  2. 2.2 Pharma and Health Care Industry Drivers
  3. 2.3 Pharma and Health Care Industry Opportunities and Challenges
  4. 2.4 Pharma and Health Care Industry Restraints
3 Pharma and Health Care Market by Company
  1. 3.1 Global Pharma and Health Care Company Revenue Ranking in 2025
  2. 3.2 Global Pharma and Health Care Revenue by Company (2021-2026)
  3. 3.3 Global Pharma and Health Care Company Ranking (2024-2026)
  4. 3.4 Global Pharma and Health Care Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharma and Health Care Company Product Type and Application
  6. 3.6 Global Pharma and Health Care Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharma and Health Care Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharma and Health Care Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharma and Health Care Market by Type
  1. 4.1 Pharma and Health Care Type Introduction
  2. 4.1.1 Bottle
  3. 4.1.2 Blister
  4. 4.1.3 Others
  5. 4.2 Global Pharma and Health Care Sales Value by Type
  6. 4.2.1 Global Pharma and Health Care Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pharma and Health Care Sales Value by Type (2021-2032)
  8. 4.2.3 Global Pharma and Health Care Sales Value Share by Type (2021-2032)
5 Pharma and Health Care Market by Application
  1. 5.1 Pharma and Health Care Application Introduction
  2. 5.1.1 OTC Drugs
  3. 5.1.2 Prescription Drugs
  4. 5.2 Global Pharma and Health Care Sales Value by Application
  5. 5.2.1 Global Pharma and Health Care Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pharma and Health Care Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pharma and Health Care Sales Value Share by Application (2021-2032)
6 Pharma and Health Care Regional Value Analysis
  1. 6.1 Global Pharma and Health Care Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharma and Health Care Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharma and Health Care Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharma and Health Care Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharma and Health Care Sales Value (2021-2032)
  7. 6.3.2 North America Pharma and Health Care Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharma and Health Care Sales Value (2021-2032)
  10. 6.4.2 Europe Pharma and Health Care Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharma and Health Care Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharma and Health Care Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharma and Health Care Sales Value (2021-2032)
  16. 6.6.2 South America Pharma and Health Care Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharma and Health Care Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharma and Health Care Sales Value Share by Country, 2025 VS 2032
7 Pharma and Health Care Country-level Value Analysis
  1. 7.1 Global Pharma and Health Care Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharma and Health Care Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharma and Health Care Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharma and Health Care Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharma and Health Care Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharma and Health Care Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharma and Health Care Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharma and Health Care Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharma and Health Care Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharma and Health Care Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharma and Health Care Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharma and Health Care Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharma and Health Care Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharma and Health Care Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharma and Health Care Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharma and Health Care Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharma and Health Care Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharma and Health Care Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharma and Health Care Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharma and Health Care Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharma and Health Care Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharma and Health Care Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharma and Health Care Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharma and Health Care Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharma and Health Care Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharma and Health Care Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharma and Health Care Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharma and Health Care Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharma and Health Care Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharma and Health Care Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharma and Health Care Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharma and Health Care Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharma and Health Care Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharma and Health Care Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Pharma and Health Care Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Pharma and Health Care Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Pharma and Health Care Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Pharma and Health Care Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Pharma and Health Care Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Pharma and Health Care Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Pharma and Health Care Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Pharma and Health Care Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Pharma and Health Care Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Pharma and Health Care Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Bristol Myers Squibb
  32. 8.6.1 Bristol Myers Squibb Company Information
  33. 8.6.2 Bristol Myers Squibb Business Overview
  34. 8.6.3 Bristol Myers Squibb Pharma and Health Care Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol Myers Squibb Pharma and Health Care Product Portfolio
  36. 8.6.5 Bristol Myers Squibb Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Pharma and Health Care Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Pharma and Health Care Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Pharma and Health Care Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Pharma and Health Care Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Pharma and Health Care Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Pharma and Health Care Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Pharma and Health Care Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Pharma and Health Care Product Portfolio
  60. 8.10.5 Takeda Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Pharma and Health Care Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Pharma and Health Care Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Pharma and Health Care Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Pharma and Health Care Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Eli Lilly & Co.
  74. 8.13.1 Eli Lilly & Co. Company Information
  75. 8.13.2 Eli Lilly & Co. Business Overview
  76. 8.13.3 Eli Lilly & Co. Pharma and Health Care Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Eli Lilly & Co. Pharma and Health Care Product Portfolio
  78. 8.13.5 Eli Lilly & Co. Recent Developments
  79. 8.14 Gilead Sciences
  80. 8.14.1 Gilead Sciences Company Information
  81. 8.14.2 Gilead Sciences Business Overview
  82. 8.14.3 Gilead Sciences Pharma and Health Care Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Gilead Sciences Pharma and Health Care Product Portfolio
  84. 8.14.5 Gilead Sciences Recent Developments
  85. 8.15 Amgen
  86. 8.15.1 Amgen Company Information
  87. 8.15.2 Amgen Business Overview
  88. 8.15.3 Amgen Pharma and Health Care Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Amgen Pharma and Health Care Product Portfolio
  90. 8.15.5 Amgen Recent Developments
  91. 8.16 Novo Nordisk
  92. 8.16.1 Novo Nordisk Company Information
  93. 8.16.2 Novo Nordisk Business Overview
  94. 8.16.3 Novo Nordisk Pharma and Health Care Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Novo Nordisk Pharma and Health Care Product Portfolio
  96. 8.16.5 Novo Nordisk Recent Developments
  97. 8.17 Teva
  98. 8.17.1 Teva Company Information
  99. 8.17.2 Teva Business Overview
  100. 8.17.3 Teva Pharma and Health Care Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Teva Pharma and Health Care Product Portfolio
  102. 8.17.5 Teva Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Pharma and Health Care Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Pharma and Health Care Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Biogen
  110. 8.19.1 Biogen Company Information
  111. 8.19.2 Biogen Business Overview
  112. 8.19.3 Biogen Pharma and Health Care Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Biogen Pharma and Health Care Product Portfolio
  114. 8.19.5 Biogen Recent Developments
  115. 8.20 Astellas
  116. 8.20.1 Astellas Company Information
  117. 8.20.2 Astellas Business Overview
  118. 8.20.3 Astellas Pharma and Health Care Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Astellas Pharma and Health Care Product Portfolio
  120. 8.20.5 Astellas Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst